Investment Committee Member — Private Real Estate
Switzerland·Property & Real Estate·Property investment· Geneva·Posted 23 September 2026
Applications close 25 October 2026
Property investment organisation in Switzerland
Partner-sourced
Sourced through a partner search firm or the sponsor's own nomination committee, and verified before listing.
The problem this seat exists to solve
The committee seeks a member who can form an independent view of property investments and explain it clearly, including when the conclusion is to decline. Candidates should have substantial underwriting or investment-approval experience and a record of reviewing outcomes after capital was committed.
Decision scope
Within the committee’s documented authority, assess acquisition, development, financing and disposal proposals. Review commercial diligence, valuation assumptions, capital requirements and downside exposure. Require the investment case to distinguish property quality from the attractiveness of the price and financing offered.
Issues that deserve deeper examination
- Correlated exposure hidden across different assets, locations or investment vehicles.
- Return assumptions dependent on refinancing, yield movement or rapid disposal.
- Unfunded maintenance and tenant or operator obligations.
- Conflicts involving originators, managers or connected counterparties.
Committee discipline
Record the basis for decisions, unresolved issues and any conditions attached to approval. Reconsider an investment when material assumptions change rather than treating prior approval as permanent authority. Voting rights and escalation to other governing bodies must follow the actual charter.
The committee’s decision record should capture the key reasons for proceeding and the assumptions most capable of changing that judgement. Post-investment review can then distinguish a reasonable decision followed by an adverse outcome from weak underwriting that happened to benefit from favourable markets. The member should challenge conditions framed so broadly that they cannot be tested. Material waivers or changes in financing, scope or price should return to the appropriate authority rather than being treated as routine execution detail.
What qualified candidates should demonstrate
Strong financial analysis must be paired with judgement about liquidity, execution and incentives. Candidates should bring anonymised examples of a rejected opportunity, a condition that protected value and an investment that underperformed despite a plausible base case. The role carries no implied requirement to raise funds or originate transactions; it is a governance contribution to capital allocation.
Terms
- Where the board sits
- Geneva, Switzerland
- Applications close
- 25 October 2026
- Appointment
- Investment committee appointment
- Time commitment in this market
- Typically 6–10 board meetings a year plus committees and a strategy retreat; SMI boards carry a heavier load than the headline count suggests.
Before you apply — Switzerland
No nationality test applies to a director. The company must be capable of being represented by someone domiciled in Switzerland, which an officer can satisfy — it does not have to be you or any other director.
- Residency test
- At least one person domiciled in Switzerland must have signing authority for the company (CO Art. 718(4)).
- Nationality test
- None.
- Work authorisation
- A non-executive director attending board meetings does not require a residence permit. Executive roles do, and non-EU/EFTA nationals face a quota system.
- Tenure limit once appointed
- No statutory cap. The Swiss Code of Best Practice asks boards to consider tenure in assessing independence and to disclose their reasoning.
Also open in Switzerland
All mandates in this market →Adviser — Portfolio Company Turnaround
Switzerland·Funds & Asset Management
Consumer and industrial investments organisation in Switzerland
The adviser will help investment decision-makers evaluate turnaround needs across operating businesses without forcing dissimilar problems into one recovery playbook. The central question is which interventions are economically justified, executable and appropriately supported by ownership.
Board Member — Compensation Committee
Switzerland·Healthcare & Life Sciences
SIX-listed life sciences company
Members of the compensation committee are elected individually by the general meeting under CO Art. 733, and shareholders vote bindingly on aggregate compensation. The company needs a member who can defend its pay architecture to international investors annually.
Global ID Exchange
One account. Every market your record travels to.
A free account applies to one mandate a week, in any market — statutory, interim or advisory — and your dashboard reads every brief that opens in the exchanges you follow. Premium removes the weekly cap.